NCT05321979

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Open-label, Single Group, Multi-center, Repeat-dose Long-term Extension Study to Evaluate the Long-term Safety and Efficacy of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 253 (actual)
• Sponsor: Medytox Korea · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.

Conditions

• Glabellar Frown Lines

Interventions

Type	Name	Description
DRUG	MBA-P01	MBA-P01 will be injected into the Glabellar line.

Timeline

• Start date: 2022-02-07
• Primary completion: 2023-05-30
• Completion: 2023-05-30
• First posted: 2022-04-11
• Last updated: 2024-01-16

Locations

1 site across 1 country: South Korea